RxDoctor Payments Data

Susan Behnawa, MD

Geriatric Medicine · Menifee, CANPI 1235558875

Payments from drug & device makers

$1,865in general payments, 2019–2025

Across 90 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$303
  • AstraZeneca$278
  • Abbott$217
  • Exact Sciences$137
  • Johnson & Johnson$131
  • AbbVie$90
  • plus $710 from 18 others

What the payments were for

  • Food & beverage$1,865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,865 in reported general payments places this provider in the 80th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$90,789
Medicare patients
299
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide260$314,603
EliquisApixaban191$212,993
MounjaroTirzepatide71$103,132
XareltoRivaroxaban62$83,026
JardianceEmpagliflozin63$56,532
JanuviaSitagliptin Phosphate40$51,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,452
FarxigaDapagliflozin Propanediol29$28,324
Spiriva HandihalerTiotropium Bromide29$23,789
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$21,568
RybelsusSemaglutide11$21,549
LinzessLinaclotide15$19,631
SantylCollagenase Clostridium Hist.12$18,221
EntrestoSacubitril/Valsartan16$15,596
Breo ElliptaFluticasone/Vilanterol27$11,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$303$336,152271 claims
PfizerEliquis$33$212,993191 claims
Lilly USA, LLCMounjaro$87$103,13271 claims
Johnson & JohnsonXarelto$131$83,02662 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$84$66,020102 claims
Boehringer IngelheimJardiance$36$56,53263 claims
AstraZenecaFarxiga, Breztri Aerosphere$278$40,04845 claims
AbbVieLinzess, Synthroid$90$26,620104 claims
NovartisEntresto$32$15,59616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Menifee

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →